Business Description
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
ISIN : CNE100004090
Share Class Description:
SHSE:603392: Class ACompare
Compare
Traded in other countries / regions
603392.China IPO Date
2020-04-29Description
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is an engaged in the research and development and production of biodiagnostic reagents and vaccines. The company produces chemiluminescence, nucleic acid, clinical biochemistry and other testing reagents and clinical inspection quality control products and vaccines. Its products include ELISA series, Colloidal gold series, Bole series, Confirmation series, Automatic blood group analyzer and reagent, Chemiluminescence series, Nucleic acid series, and Research Series.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 18.99 | |||||
| Equity-to-Asset | 0.81 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.22 | |||||
| Interest Coverage | 236.39 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 19.83 | |||||
| Beneish M-Score | -2.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 30.4 | |||||
| 3-Year EBITDA Growth Rate | 22.1 | |||||
| 3-Year EPS without NRI Growth Rate | 18 | |||||
| 3-Year FCF Growth Rate | 66.5 | |||||
| 3-Year Book Growth Rate | 69.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.14 | |||||
| 9-Day RSI | 33.39 | |||||
| 14-Day RSI | 39.37 | |||||
| 6-1 Month Momentum % | 71.61 | |||||
| 12-1 Month Momentum % | -5.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.86 | |||||
| Quick Ratio | 3.52 | |||||
| Cash Ratio | 2.2 | |||||
| Days Inventory | 459.16 | |||||
| Days Sales Outstanding | 274.18 | |||||
| Days Payable | 156.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.55 | |||||
| Dividend Payout Ratio | 0.77 | |||||
| Forward Dividend Yield % | 1.55 | |||||
| 5-Year Yield-on-Cost % | 1.55 | |||||
| 3-Year Average Share Buyback Ratio | -1 | |||||
| Shareholder Yield % | 1.45 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 85.63 | |||||
| Operating Margin % | 29.43 | |||||
| Net Margin % | 22.64 | |||||
| FCF Margin % | 6.86 | |||||
| ROE % | 9.58 | |||||
| ROA % | 7.59 | |||||
| ROIC % | 19.65 | |||||
| ROC (Joel Greenblatt) % | 28.15 | |||||
| ROCE % | 10.44 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 64.04 | |||||
| PE Ratio without NRI | 48.88 | |||||
| Shiller PE Ratio | 78.27 | |||||
| Price-to-Owner-Earnings | 116.31 | |||||
| PEG Ratio | 0.83 | |||||
| PS Ratio | 14.53 | |||||
| PB Ratio | 6.33 | |||||
| Price-to-Tangible-Book | 6.67 | |||||
| Price-to-Free-Cash-Flow | 209.25 | |||||
| Price-to-Operating-Cash-Flow | 51.82 | |||||
| EV-to-EBIT | 54.72 | |||||
| EV-to-EBITDA | 54.72 | |||||
| EV-to-Revenue | 13.9 | |||||
| EV-to-FCF | 209.04 | |||||
| Price-to-Projected-FCF | 4.69 | |||||
| Price-to-DCF (Earnings Based) | 1.56 | |||||
| Price-to-DCF (FCF Based) | 6.69 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.98 | |||||
| Price-to-Graham-Number | 3.81 | |||||
| Price-to-Net-Current-Asset-Value | 11.03 | |||||
| Price-to-Net-Cash | 28.18 | |||||
| Earnings Yield (Greenblatt) % | 1.83 | |||||
| FCF Yield % | 0.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 5,510.783 | ||
| EPS (TTM) (Â¥) | 0.99 | ||
| Beta | 1.59 | ||
| Volatility % | 82.93 | ||
| 14-Day RSI | 39.37 | ||
| 14-Day ATR (Â¥) | 3.640988 | ||
| 20-Day SMA (Â¥) | 68.1805 | ||
| 12-1 Month Momentum % | -5.3 | ||
| 52-Week Range (Â¥) | 40.14 - 88 | ||
| Shares Outstanding (Mil) | 1,268.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Frequently Asked Questions
What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd(SHSE:603392)'s stock price today?
The current price of SHSE:603392 is ¥63.40. The 52 week high of SHSE:603392 is ¥88.00 and 52 week low is ¥40.14.
When is next earnings date of Beijing Wantai Biological Pharmacy Enterprise Co Ltd(SHSE:603392)?
The next earnings date of Beijing Wantai Biological Pharmacy Enterprise Co Ltd(SHSE:603392) is .
Does Beijing Wantai Biological Pharmacy Enterprise Co Ltd(SHSE:603392) pay dividends? If so, how much?
The Dividend Yield %  of Beijing Wantai Biological Pharmacy Enterprise Co Ltd(SHSE:603392) is 1.55% (As of Today), Highest Dividend Payout Ratio of Beijing Wantai Biological Pharmacy Enterprise Co Ltd(SHSE:603392) was 1.18. The lowest was 0.04. And the median was 0.06. The  Forward Dividend Yield % of Beijing Wantai Biological Pharmacy Enterprise Co Ltd(SHSE:603392) is 1.55%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers